


Supplementary Figure S1. Progression-free survival (PFS) and overall survival (OS) in melanoma patients receiving anti-PD-1 antibodies. The numbers below the charts correspond to patients at risk at each time point.



Supplementary Figure S2. Progression-free survival (PFS) (A, C, E) and overall survival (OS) (B, D, F) in melanoma patients receiving anti-PD-1 antibodies, who had skin (A, B), vitiligo (C, D), and endocrine (E, F) irAEs

The patients experiencing skin/vitiligo (C, $p = 0.092$) and endocrine (E, $p = 0.094$) irAEs showed a trend of favorable PFS. The patients experiencing skin ($p = 0.054$), vitiligo ($p = 0.047$), and endocrine ($p = 0.062$) irAEs had a trend of favorable OS. The numbers below the charts correspond to patients at risk at each time point.

irAEs, immune-related adverse events